Reducing the burden of hereditary angioedema (HAE) could be possible with adequate dosing and frequency of administration of C1 inhibitor (C1-INH), even for patients with highly symptomatic HAE activity, according to data from randomized controlled trials evaluating the administration of C1-INH replacement therapy as long-term prophylaxis in patients with HAE. Up to 83% of patients…
The diagnosis and management of patients with hereditary angioedema (HAE) who reside in rural communities present particular challenges, according to findings from an online survey conducted in the United States and published in the Annals of Allergy, Asthma & Immunology. The researchers sought to explore the experiences of allergy and immunology health care professionals in…
People with hereditary angioedema (HAE) suffered stress-related sequelae during the COVID-19 pandemic, including enhanced disease morbidity and reduced quality of life, according to an article published in the journal Allergy and Asthma Proceedings. The researchers recruited people with HAE, both due to C1-inhibitor deficiency and those with normal C1-inhibitor levels, as well as their household…
Patients in Japan with hereditary angioedema (HAE) experience a heavy burden of illness in the physical, social, psychosocial, and economic domains, which is associated with reduced health-related quality of life (HRQoL), according to findings from a patient-reported outcome (PRO) survey published in Intractable & Rare Diseases Research. HAE is a rare, potentially life-threatening disorder linked…
The US Food and Drug Administration (FDA) has accepted Intellia Therapeutics’ Investigational New Drug (IND) application for NTLA-2002, a potential gene editing therapy for hereditary angioedema (HAE), the company announced. The acceptance, announced via news release, allows the company to include the United States in its global phase 2 clinical study. “The FDA’s acceptance of…
Intrauterine sex hormone exposure, which affects the ratio of the second and fourth finger lengths (2D:4D), may be associated with hereditary angioedema (HAE) attack frequency and severity as well as laryngeal edema, according to a study published in Early Human Development. The study authors evaluated 35 patients with HAE aged 19 to 66 years, 3 of…
A patient with hereditary angioedema with normal C1 inhibitor (HAE-nC1) and negative genetic testing experienced reduced attack severity and approximately 80% lower attack frequency as a result of treatment with anti-kallikrein biologic medication lanadelumab, according to a case report published in the Journal of Allergy and Clinical Immunology: Global. The study authors reported on a…
Ionis Pharmaceuticals reported positive results from a phase 2 open-label extension study of donidalorsen, a novel therapy designed to treat patients with hereditary angioedema (HAE). Donidalorsen is a ligand-conjugated antisense oligonucleotide created to reduce the production of hepatic prekallikrein, which has been implicated in the pathophysiology of HAE. A total of 20 patients with either…
In patients with hereditary angioedema (HAE), treatment with long-term prophylaxis has been associated with improved quality of life (QoL) compared to acute therapy, according to findings from recent telephone call surveys utilizing 4 different questionnaires. Results of the analysis were presented at the 2023 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting held…
A new study has found that solitary individuals with chronic recurrent angioedema (CRA) that does not respond to antihistamines can include patients with hereditary angioedema (HAE) with normal C1 inhibitor (HAEnCI). The study, published in the Journal of Allergy and Clinical Immunology: In Practice, recommends searching for HAEnCI-linked mutations in these individuals to detect asymptomatic…
Please login or register first to view this content.
